![Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace](https://mms.businesswire.com/media/20180914005613/en/678526/4/AJOVY+Image.jpg)
Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace
![Teva Pharmaceuticals Announces Launch of Daily Maintenance Asthma Medication | Asthma and Allergy Foundation of America Teva Pharmaceuticals Announces Launch of Daily Maintenance Asthma Medication | Asthma and Allergy Foundation of America](https://community.aafa.org/fileSendAction/fcType/0/fcOid/510642830861510679/filePointer/510642830861510701/fodoid/510642830861510696/imageType/MEDIUM/inlineImage/true/Teva-announced-launch-of-new-daily-asthma-medicine.png)
Teva Pharmaceuticals Announces Launch of Daily Maintenance Asthma Medication | Asthma and Allergy Foundation of America
![Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder](https://mms.businesswire.com/media/20200921005170/en/819864/4/Interactive_Media_Placeholder_webready.jpg)
Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder
![Teva Pharmaceuticals Recalls Acute Myeloid Leukemia Drug Over Particulate Matter Contamination - Top Class Actions Teva Pharmaceuticals Recalls Acute Myeloid Leukemia Drug Over Particulate Matter Contamination - Top Class Actions](https://s40123.pcdn.co/wp-content/uploads/2022/03/recallTeva.jpg.optimal.jpg)